Medical Malpractice and Sarcoma Care-A Thirty-Three Year Review of Case Resolutions, Inciting Factors, and At Risk Physician Specialties Surrounding a Rare Diagnosis

被引:21
作者
Mesko, Nathan W. [1 ]
Mesko, Jennifer L. [1 ]
Gaffney, Lauren M. [1 ]
Halpern, Jennifer L. [1 ]
Schwartz, Herbert S. [1 ]
Holt, Ginger E. [1 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Orthopaed Surg, Musculoskeletal Oncol Div, Nashville, TN USA
关键词
sarcoma; medical malpractice; delay in diagnosis; SOFT-TISSUE SARCOMA; NATIONAL-HEALTH-SERVICE; LOW-BACK-PAIN; AMERICAN-COLLEGE; CLOSED CLAIMS; TUMOR SURGERY; BONE; LITIGATION; SYMPTOMS; HAZARDS;
D O I
10.1002/jso.23770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundWe reviewed medico-legal cases related to extremity sarcoma malpractice in order to recognize those factors most commonly instigating sarcoma litigation. MethodsOver one million legal cases available in a national legal database were searched for malpractice verdicts and settlements involving extremity sarcoma spanning 1980-2012. We categorized verdict/settlement resolutions by state, year, award amount, nature of the complaint/injury, specialty of the physician defendant, and academic affiliation of defendant-amongst other variables. ResultsOf the 216 cases identified, 57% of case resolutions favored the plaintiff, with a mean indemnity payment of $2.30 million (range $65,076-$12.66 million). Delay in diagnosis (81%), unnecessary amputation (11%), and misdiagnosis (7%) accounted for the majority of complaints. The greatest numbers of claims were filed against primary care specialties (34%), orthopaedic surgeons (23%), and radiologists (12%). Individual state tort reform measures were not protective against case resolution outcome. ConclusionsReported medico-legal claims involving sarcoma care continue to rise, with mean indemnity payments approaching 10 times that for other reported medical/surgical specialties. Primary care and orthopaedic specialties are the most commonly named physician defendants, citing a delay in diagnosis. This suggests further education in the front line diagnosis and management of sarcomas is needed. J. Surg. Oncol. 2014; 110:919-929. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:919 / 929
页数:11
相关论文
共 37 条
[21]   THE HAZARDS OF BIOPSY IN PATIENTS WITH MALIGNANT PRIMARY BONE AND SOFT-TISSUE TUMORS [J].
MANKIN, HJ ;
LANGE, TA ;
SPANIER, SS .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1982, 64 (08) :1121-1127
[22]  
Markides GA, 2014, COLORECTAL DIS, V16, P48, DOI 10.1111/codi.12408
[23]   The Management of Adult Soft Tissue Sarcomas [J].
Mendenhall, William M. ;
Indelicato, Daniel J. ;
Scarborough, Mark T. ;
Zlotecki, Robert A. ;
Gibbs, C. Parker ;
Mendenhall, Nancy P. ;
Mendenhall, Charles M. ;
Enneking, William F. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04) :436-442
[24]  
Miller Robert A, 2012, J Bone Joint Surg Am, V94, pe18, DOI 10.2106/JBJS.K.00646
[25]   Trends in malpractice litigation in relation to the delivery of breast care in the National Health Service [J].
Morgan, Jenna L. ;
Vijh, Rajesh .
BREAST, 2013, 22 (05) :964-967
[26]   Impact of Hospital Volume on Postoperative Complications and In-Hospital Mortality After Musculoskeletal Tumor Surgery Analysis of a National Administrative Database [J].
Ogura, Koichi ;
Yasunaga, Hideo ;
Horiguchi, Hiromasa ;
Ohe, Kazuhiko ;
Shinoda, Yusuke ;
Tanaka, Sakae ;
Kawano, Hirotaka .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2013, 95A (18) :1684-1691
[27]  
Papadonikolakis A, 2013, J BONE JOINT SURG AM, V95A, P2205, DOI [10.2106/JBJS.L.00552, 10.2106/JBJS.K.01272]
[28]   Does length of symptoms before diagnosis of sarcoma affect patient survival? [J].
Rougraff, Bruce T. ;
Davis, Kenneth ;
Lawrence, Jackie .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2007, (462) :181-189
[29]   Length of Symptoms Before Referral: Prognostic Variable for High-grade Soft Tissue Sarcoma? [J].
Rougraff, Bruce T. ;
Lawrence, Jackie ;
Davis, Kenneth .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2012, 470 (03) :706-711
[30]  
Scheiber SJ, 2009, UNSUSTAINABLE COST H, P11